$SLNO
SOLENO THERAPEUTICS INC

2014 Q4 Form 10-Q Financial Statement

#000119312514446943 Filed on December 18, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.240M $606.0K $200.0K
YoY Change 520.0% 142.4%
% of Gross Profit
Research & Development $610.0K $717.0K $360.0K
YoY Change 69.44% -3.76%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.850M $1.323M $560.0K
YoY Change 230.36% 33.23%
Operating Profit -$1.323M
YoY Change 33.23%
Interest Expense -$2.320M $752.0K -$390.0K
YoY Change 494.87% 31.7%
% of Operating Profit
Other Income/Expense, Net -$3.690M -$1.070M -$30.00K
YoY Change 12200.0% 4015.38%
Pretax Income -$7.860M -$2.390M -$970.0K
YoY Change 710.31% 50.31%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.860M -$2.393M -$970.0K
YoY Change 710.31% 50.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$31.44M -$1.770M -$621.8K
COMMON SHARES
Basic Shares Outstanding 6.769M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.960M $60.00K $1.270M
YoY Change 526.77%
Cash & Equivalents $7.957M $64.00K $1.269M
Short-Term Investments
Other Short-Term Assets $270.0K $210.0K $110.0K
YoY Change 145.45%
Inventory $109.3K
Prepaid Expenses
Receivables $0.00 $37.00K $149.6K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.338M $307.0K $1.524M
YoY Change 447.3%
LONG-TERM ASSETS
Property, Plant & Equipment $57.61K $36.00K $63.17K
YoY Change -8.8%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.350M $0.00
YoY Change
Total Long-Term Assets $57.61K $1.389M $63.17K
YoY Change -8.8%
TOTAL ASSETS
Total Short-Term Assets $8.338M $307.0K $1.524M
Total Long-Term Assets $57.61K $1.389M $63.17K
Total Assets $8.396M $1.696M $1.587M
YoY Change 429.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $986.8K $1.238M $57.72K
YoY Change 1609.6%
Accrued Expenses $200.0K $358.0K $129.0K
YoY Change 55.04%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $0.00 $13.99M
YoY Change -99.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.290M $1.596M $14.18M
YoY Change -90.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $18.67M $1.460M
YoY Change -100.0%
Total Long-Term Liabilities $18.30M $18.67M $1.460M
YoY Change 1153.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.290M $1.596M $14.18M
Total Long-Term Liabilities $18.30M $18.67M $1.460M
Total Liabilities $19.59M $20.27M $15.64M
YoY Change 25.23%
SHAREHOLDERS EQUITY
Retained Earnings -$70.34M -$63.12M -$57.10M
YoY Change 23.18%
Common Stock $59.15M $20.74M $19.24M
YoY Change 207.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.19M -$42.38M -$34.20M
YoY Change
Total Liabilities & Shareholders Equity $8.396M $1.696M $1.587M
YoY Change 429.15%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$7.860M -$2.393M -$970.0K
YoY Change 710.31% 50.5%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$1.550M -$1.260M -$730.0K
YoY Change 112.33% 36.96%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$30.00K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.480M 110.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.550M -1.260M -730.0K
Cash From Investing Activities -30.00K 0.000 0.000
Cash From Financing Activities 9.480M 110.0K 0.000
Net Change In Cash 7.900M -1.150M -730.0K
YoY Change -1182.19% 25.0%
FREE CASH FLOW
Cash From Operating Activities -$1.550M -$1.260M -$730.0K
Capital Expenditures -$30.00K $0.00 $0.00
Free Cash Flow -$1.520M -$1.260M -$730.0K
YoY Change 108.22% 36.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
535685 shares
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6769106 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1992000
CY2014Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
100000
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
535685 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
228224 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.59
CY2014Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1860000 shares
CY2014Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
865429 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
3066258
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1596000
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3066000
CY2014Q3 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
23808048
CY2014Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1238000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63120000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
20741000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
358000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-42378000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
73000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1696000
CY2014Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
15604000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64000
CY2014Q3 us-gaap Deferred Costs
DeferredCosts
1353000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
186000
CY2014Q3 us-gaap Assets
Assets
1696000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
307000
CY2014Q3 capn Fair Value Of Common Stock
FairValueOfCommonStock
7.56
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2155000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
535685 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
535685 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
232302 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.36
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1463877
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14179000
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1464000
CY2013Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
23808048
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
58000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57100000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19235000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
129000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-37864000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1587000
CY2013Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
13992000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1269000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
85000
CY2013Q4 us-gaap Assets
Assets
1587000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
150000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
1524000
CY2013Q4 capn Fair Value Of Common Stock
FairValueOfCommonStock
7.56
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-163000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
535611 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.10
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9000
us-gaap Operating Income Loss
OperatingIncomeLoss
-287000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-151000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
103000
us-gaap Revenues
Revenues
3000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
us-gaap Net Income Loss
NetIncomeLoss
-2733000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
97000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35000
us-gaap Interest Expense
InterestExpense
2550000
us-gaap Operating Expenses
OperatingExpenses
3287000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2020000
us-gaap Interest Expense Debt
InterestExpenseDebt
2471000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-164000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
79000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
234000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
32000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1267000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the Board of Directors, subject to the prior rights of all classes of stock outstanding. The holders of common stock, voting as a separate class, are entitled to elect one member of the Board of Directors.
us-gaap Liquidity Disclosure Going Concern Note
LiquidityDisclosureGoingConcernNote
As of September 30, 2014, there was substantial doubt about our ability to continue as a going concern, if we did not secure additional financing. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our 2013 financial statements with respect to this uncertainty. However, as described more fully below, since September 30, 2014, we completed our IPO and received net proceeds of $8.2 million, after deducting underwriting discounts and commissions and IPO related expenses. We believe that our cash resources are sufficient to meet our cash needs for at least the next 12 months.
us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2014-09-29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y4M24D
dei Document Type
DocumentType
10-Q
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Registrant Name
EntityRegistrantName
Capnia, Inc.
dei Trading Symbol
TradingSymbol
CAPN
us-gaap Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger
DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
0.75 pure
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of each share of Series A, Series B and Series C would have been entitled to voting rights equal to the number of shares of common stock into which each share of preferred stock would have been converted. So long as at least 1,000,000 shares are outstanding, the holders of Series A, Series B and Series C, voting together as a single class, would have been entitled to elect three members of the Board of Directors. The holders of common stock, voting as a separate class, would have been entitled to elect one member of the Board of Directors. The holders of Series A, Series B, Series C and common stock, voting together as a single class on an as converted basis, would have been entitled to elect the remaining members of the Board of Directors.
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1999-08-25
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of Series A, Series B and Series C would have been convertible to common stock, at the option of the holder, at any time after the date of issuance. Each share of Series A, Series B and Series C converts into that number of shares of common stock determined in accordance with the conversion ratio (i) immediately prior to the closing of a public offering of common stock provided that the offering price per share is not less than $75.60 (adjusted for recapitalizations) and gross proceeds to the Company are not less than $30,000,000 or (ii) upon the written request by the Company from the holders of two thirds of the preferred stock outstanding.
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2928000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0 shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets and the valuation of debt and equity instruments and stock-based compensation.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
535685 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.060 pure
dei Entity Central Index Key
EntityCentralIndexKey
0001484565
us-gaap Convertible Preferred Stock Settlement Terms
ConvertiblePreferredStockSettlementTerms
The initial conversion ratio would have been one share of common stock for each share of preferred stock.
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.24
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
The line of credit bears a fixed interest rate of 6.0% per annum simple interest.
us-gaap Operating Income Loss
OperatingIncomeLoss
-3314000
us-gaap Interest Expense Debt
InterestExpenseDebt
1811000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1205000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
1484000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-895000
us-gaap Net Income Loss
NetIncomeLoss
-6019000
us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
888000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
177000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
20000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-112000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
276000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
101000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
0
us-gaap Interest Expense
InterestExpense
1811000
us-gaap Operating Expenses
OperatingExpenses
3314000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1633000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
96000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1723000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
229000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1997000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1585000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
103000
capn Operating Leases Expiration Date
OperatingLeasesExpirationDate
2015-05
capn Number Of Payments To Redeem Convertible Preferred Stock
NumberOfPaymentsToRedeemConvertiblePreferredStock
2 Payment
capn Convertible Preferred Stock Earliest Redemption Date
ConvertiblePreferredStockEarliestRedemptionDate
2012-03-20
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12683 shares
capn Deferred Offering Costs Included In Accounts Payable
DeferredOfferingCostsIncludedInAccountsPayable
1077000
capn Issuance Of Warrants In Connection With Notes Payable
IssuanceOfWarrantsInConnectionWithNotesPayable
713000
capn Minimum Shares Outstanding For Voting Rights
MinimumSharesOutstandingForVotingRights
1000000 shares
capn Number Of Previously Leased Facilities
NumberOfPreviouslyLeasedFacilities
2 Facilities
capn Convertible Preferred Stock Conversion Terms Common Stock Offering Minimum Price Per Share
ConvertiblePreferredStockConversionTermsCommonStockOfferingMinimumPricePerShare
75.60
capn Convertible Preferred Stock Conversion Terms Common Stock Offering Minimum Gross Proceeds
ConvertiblePreferredStockConversionTermsCommonStockOfferingMinimumGrossProceeds
30000000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y10M10D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
535685 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.97
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-993000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1590000
CY2013Q3 us-gaap Interest Expense
InterestExpense
571000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
993000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
745000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
248000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
535685 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.47
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1323000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-318000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2393000
CY2014Q3 us-gaap Interest Expense
InterestExpense
752000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1323000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
717000
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
84000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
522000

Files In Submission

Name View Source Status
0001193125-14-446943-index-headers.html Edgar Link pending
0001193125-14-446943-index.html Edgar Link pending
0001193125-14-446943.txt Edgar Link pending
0001193125-14-446943-xbrl.zip Edgar Link pending
capn-20140930.xml Edgar Link completed
capn-20140930.xsd Edgar Link pending
capn-20140930_cal.xml Edgar Link unprocessable
capn-20140930_def.xml Edgar Link unprocessable
capn-20140930_lab.xml Edgar Link unprocessable
capn-20140930_pre.xml Edgar Link unprocessable
d829496d10q.htm Edgar Link pending
d829496dex311.htm Edgar Link pending
d829496dex312.htm Edgar Link pending
d829496dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending